FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281713> ?p ?o ?g. }

• W4379281713 endingPage "TPS5620" @default.
• W4379281713 startingPage "TPS5620" @default.
• W4379281713 abstract "TPS5620 Background: OC is the fifth most common cause of death from cancer in women. More than 70% of the patients are diagnosed with advanced disease and less than 40% of women with OC are cured. Currently, the standard therapy in HRD OC is surgical debulking followed by 6 cycles of chemotherapy with subsequent maintenance treatment with poly ADP ribose polymerase (PARP) inhibitors. Within the last decades, no focus was set on the benefits of fewer cycles of chemotherapy, even though there is evidence for comparable efficacy and less toxicity in comparison to more cycles. Chemotherapies are usually associated with side effects, which can be severe and even lead to therapy discontinuation. The data available about the needed number of chemotherapy cycles is weak, especially in the context of PARP inhibition. Furthermore, patients with stage III/IV with optimal cytoreduction are underrepresented in previous studies. In the N-PLUS trial, we hypothesize that recurrence-free survival (RFS) in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRD high-grade OC patients with no visible disease following primary tumor debulking. Methods: In this multicenter, randomized, open-label study 650 patients with advanced HRD high-grade OC with no residual tumor mass following primary tumor debulking will be enrolled. Patients will be randomized 1:1 to receive either 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (Arm A) or 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (Arm B) for a maximum of 36 months. Randomization will be performed according to the results of the NGS analysis and stratified either to BRCAm/LOH-independent or BRCAwt/LOHhigh, FIGO stage III vs. IV, and participating countries. The primary endpoint will be RFS, secondary endpoints will be OS, TFST, TWIST, PFS2, Quality of Life and safety assessments. Clinical trial information: NCT05460000 ." @default.
• W4379281713 created "2023-06-05" @default.
• W4379281713 creator A5002555374 @default.
• W4379281713 creator A5020736525 @default.
• W4379281713 creator A5026862587 @default.
• W4379281713 creator A5029949952 @default.
• W4379281713 creator A5032677101 @default.
• W4379281713 creator A5063818378 @default.
• W4379281713 creator A5065403378 @default.
• W4379281713 creator A5068601323 @default.
• W4379281713 creator A5080757346 @default.
• W4379281713 date "2023-06-01" @default.
• W4379281713 modified "2023-09-30" @default.
• W4379281713 title "First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62)." @default.
• W4379281713 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps5620" @default.
• W4379281713 hasPublicationYear "2023" @default.
• W4379281713 type Work @default.
• W4379281713 citedByCount "0" @default.
• W4379281713 crossrefType "journal-article" @default.
• W4379281713 hasAuthorship W4379281713A5002555374 @default.
• W4379281713 hasAuthorship W4379281713A5020736525 @default.
• W4379281713 hasAuthorship W4379281713A5026862587 @default.
• W4379281713 hasAuthorship W4379281713A5029949952 @default.
• W4379281713 hasAuthorship W4379281713A5032677101 @default.
• W4379281713 hasAuthorship W4379281713A5063818378 @default.
• W4379281713 hasAuthorship W4379281713A5065403378 @default.
• W4379281713 hasAuthorship W4379281713A5068601323 @default.
• W4379281713 hasAuthorship W4379281713A5080757346 @default.
• W4379281713 hasConcept C104317684 @default.
• W4379281713 hasConcept C121608353 @default.
• W4379281713 hasConcept C126322002 @default.
• W4379281713 hasConcept C141071460 @default.
• W4379281713 hasConcept C143998085 @default.
• W4379281713 hasConcept C151730666 @default.
• W4379281713 hasConcept C168563851 @default.
• W4379281713 hasConcept C182979987 @default.
• W4379281713 hasConcept C185592680 @default.
• W4379281713 hasConcept C203092338 @default.
• W4379281713 hasConcept C2776694085 @default.
• W4379281713 hasConcept C2777292972 @default.
• W4379281713 hasConcept C2778239845 @default.
• W4379281713 hasConcept C2778283404 @default.
• W4379281713 hasConcept C2778715236 @default.
• W4379281713 hasConcept C2779138821 @default.
• W4379281713 hasConcept C2779343474 @default.
• W4379281713 hasConcept C2780427987 @default.
• W4379281713 hasConcept C2781100745 @default.
• W4379281713 hasConcept C2781451048 @default.
• W4379281713 hasConcept C55493867 @default.
• W4379281713 hasConcept C71924100 @default.
• W4379281713 hasConcept C82381507 @default.
• W4379281713 hasConcept C86803240 @default.
• W4379281713 hasConceptScore W4379281713C104317684 @default.
• W4379281713 hasConceptScore W4379281713C121608353 @default.
• W4379281713 hasConceptScore W4379281713C126322002 @default.
• W4379281713 hasConceptScore W4379281713C141071460 @default.
• W4379281713 hasConceptScore W4379281713C143998085 @default.
• W4379281713 hasConceptScore W4379281713C151730666 @default.
• W4379281713 hasConceptScore W4379281713C168563851 @default.
• W4379281713 hasConceptScore W4379281713C182979987 @default.
• W4379281713 hasConceptScore W4379281713C185592680 @default.
• W4379281713 hasConceptScore W4379281713C203092338 @default.
• W4379281713 hasConceptScore W4379281713C2776694085 @default.
• W4379281713 hasConceptScore W4379281713C2777292972 @default.
• W4379281713 hasConceptScore W4379281713C2778239845 @default.
• W4379281713 hasConceptScore W4379281713C2778283404 @default.
• W4379281713 hasConceptScore W4379281713C2778715236 @default.
• W4379281713 hasConceptScore W4379281713C2779138821 @default.
• W4379281713 hasConceptScore W4379281713C2779343474 @default.
• W4379281713 hasConceptScore W4379281713C2780427987 @default.
• W4379281713 hasConceptScore W4379281713C2781100745 @default.
• W4379281713 hasConceptScore W4379281713C2781451048 @default.
• W4379281713 hasConceptScore W4379281713C55493867 @default.
• W4379281713 hasConceptScore W4379281713C71924100 @default.
• W4379281713 hasConceptScore W4379281713C82381507 @default.
• W4379281713 hasConceptScore W4379281713C86803240 @default.
• W4379281713 hasIssue "16_suppl" @default.
• W4379281713 hasLocation W43792817131 @default.
• W4379281713 hasOpenAccess W4379281713 @default.
• W4379281713 hasPrimaryLocation W43792817131 @default.
• W4379281713 hasRelatedWork W2020778541 @default.
• W4379281713 hasRelatedWork W2072767112 @default.
• W4379281713 hasRelatedWork W2105623825 @default.
• W4379281713 hasRelatedWork W2157919202 @default.
• W4379281713 hasRelatedWork W2311734504 @default.
• W4379281713 hasRelatedWork W2410995755 @default.
• W4379281713 hasRelatedWork W2919970378 @default.
• W4379281713 hasRelatedWork W2968124559 @default.
• W4379281713 hasRelatedWork W4286299135 @default.
• W4379281713 hasRelatedWork W99287364 @default.
• W4379281713 hasVolume "41" @default.
• W4379281713 isParatext "false" @default.
• W4379281713 isRetracted "false" @default.
• W4379281713 workType "article" @default.